With over 200 formulations already screened and fully compliant with 21 CFR Parts 170-199 (FDA) and/or Reg. (EU) No. 10/2011 (formerly Directive 2002/72/EC), Reg. (EC) No. 1935/2004, ten products NSF/ANSI 51 and 61 listed, LATI S.p.A. can cover the full product portfolio.
These preliminary certifications are often a good starting point for non critical healthcare applications. Cytotoxicity can be assessed upon request on selected products.